Our targeted multi-cancer panels track epigenomic signals to detect the disease early.
The ClearNote Health approach to detecting cancer early is anchored in epigenomics by tracking changes in cells in the body. With the current focus on pancreatic and ovarian cancers, we aim to address unmet patient needs through early and focused cancer detection through a simple blood draw. Unlike existing cancer screening methods, our 5hmC-based proprietary technology platform provides a comprehensive view of tumor biology to inform patient diagnosis and treatment journey. Our R&D pipeline includes multiple single-cancer and focused multi-cancer tests to help people at high risk of developing high-mortality cancers live longer and healthier lives.